CONFERENCE BRIEF: 2026 Drug Channels Leadership Forum
By Julia Hancock, IIS VP of Trade & Commercial Growth
The 2026 Drug Channels Leadership Forum (DCLF) brought together senior leaders from across the pharmaceutical ecosystem, including manufacturers, providers, payers, and innovators, for candid conversations on the forces reshaping healthcare.
With participation from organizations like AstraZeneca, Boehringer Ingelheim, Cardinal Health, Prime Therapeutics, and industry disruptors like Mark Cuban, the message was clear: the U.S. drug channel is at a pivotal moment of change.
Key Themes That Matter to You
1. 340B: Growing Complexity and Scrutiny
The 340B program continues to expand, but so do questions around its structure and impact. Discussions highlighted increasing tension between hospitals, manufacturers, and policymakers, particularly around program intent, transparency, and financial flow.
Why it matters: Both providers and manufacturers should expect continued policy attention and potential changes that could impact margins and access.
2. Provider-Administered Drugs & Buy-and-Bill Pressures
Reimbursement models for provider-administered drugs are under increasing pressure, especially as CMS policies and ASP-based reimbursement evolve.
Why it matters:
Providers may see margin compression and site-of-care shifts
Manufacturers may need to rethink pricing and distribution strategies
3. CMS and Pricing Reform Are Reshaping Strategy
Ongoing policy changes—including CMS reimbursement updates and broader pricing reforms—are driving a shift in how drugs are priced and reimbursed.
Why it matters: Expect greater scrutiny on pricing models, with ripple effects across contracting, access, and patient affordability.
4. Vertical Integration Is Changing the Rules
The continued growth of vertically integrated healthcare organizations (PBMs, insurers, specialty pharmacies, and providers) is reshaping how decisions are made across the channel.
Why it matters:
Access is increasingly controlled through integrated entities
Contracting and distribution strategies must adapt to fewer, more powerful decision-makers
5. New Models Are Challenging the Status Quo
Emerging approaches—such as transparent, cash-pay pricing models—are gaining traction and challenging traditional rebate-driven systems.
Why it matters:
These models signal a growing demand for simplicity, transparency, and patient-centered pricing.
What This Means Moving Forward
Across all discussions, one takeaway stood out:
No single stakeholder controls the system anymore. Success depends on understanding how all parts of the drug channel connect.
For manufacturers, this means aligning pricing, access, and distribution strategies more closely than ever.
For providers, it means navigating reimbursement changes while maintaining sustainable patient care models.
The conversations at DCLF 2026 reinforced that the healthcare system is not just evolving… it is being redefined in real time. Organizations that stay informed, adaptable, and collaborative will be best positioned to navigate what comes next.
Julia Hancock, IIS VP of Trade & Commercial Growth
